The potential value of Glycoprotein IIb/IIIa receptor antagonists for the medical treatment of acute coronary syndromes remains uncertain pending the results of large randomized trials.
Answers are grounded in this paper and cite their sources.
GP IIb/IIIa antagonists should not yet alter ACS medical management; large RCTs needed to resolve uncertainty.
Glycoprotein IIb/IIIa receptor antagonists are more potent platelet inhibitors than aspirin. Although important reductions in ischemic/thrombotic complications have been observed with these agents following coronary interventions, their potential value for the medical treatment of acute coronary syndromes is at present uncertain. The final results of large randomized studies in patients with acute coronary syndromes are eagerly awaited.
No takes yet. Share an insight, caveat, or question.
Frans Van de Werf (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: